An open-label study of escitalopram (Lexapro®) for the treatment of 'depression of Alzheimer's disease' (dAD)

V. Rao, J. R. Spiro, P. B. Rosenberg, H. B. Lee, A. Rosenblatt, C. G. Lyketsos

Research output: Contribution to journalArticle


Background: Depression is a frequent neuropsychiatric complication of Alzheimer's Disease. Methods: This study investigated the safety and effectiveness of escitalopram (LEXAPRO) for depression in AD (dAD) as defined by the NIMH consensus criteria in an 8-week, open-label treatment study. Conclusion: Escitalopram was efficacious and safe for the treatment of dAD in this study. Larger, controlled studies are warranted to further assess the efficacy for mood and behavioral disturbances in this medically fragile population.

Original languageEnglish (US)
Pages (from-to)273-274
Number of pages2
JournalInternational journal of geriatric psychiatry
Issue number3
StatePublished - Mar 1 2006



  • Depression in Alzheimer's disease
  • Escitalopram

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this